Share-Based Compensation (Tables)

6 Months Ended

Dec. 31, 2018

Share-Based Compensation

Schedule of weighted average assumptions used to estimate fair values of the stock options granted and the estimated annual forfeiture rates used to recognize the associated compensation expense and the weighted average fair value of the options granted

	Six Months Ended
	December 31, 2018			December 31, 2017
Risk-free interest rate		2.9	%		1.9	%
Expected volatility		58.4	%		57.4	%
Expected dividend yield		—	%		—	%
Forfeiture rate		6.5	%		6.5	%
Expected term (in years)		5.3	years		5.4	years
Weighted average fair value	$	6.52		$	9.06

Summary of stock option award activity

						Weighted
		Weighted-				Average
		Average		Aggregate		Remaining
		Exercise		Intrinsic		Contractual
(In thousands, except for weighted average price and life data)	Awards	Price		Value		Life (yrs.)
Outstanding at June 30, 2018	1,057	$	22.46	$	2,584	5.4
Granted	73	$	12.20		—
Exercised	(32)	$	4.39	$	141
Forfeited, expired or repurchased	(336)	$	34.95
Outstanding at December 31, 2018	762	$	16.71	$	170	5.2
Vested and expected to vest at December 31, 2018	752	$	16.74	$	170	5.1
Exercisable at December 31, 2018	648	$	16.84	$	170	4.4

Summary of non-vested restricted stock awards

		Weighted
		Average Grant -		Aggregate
(In thousands, except for weighted average price and life data)	Awards	date Fair Value		Intrinsic Value
Non-vested at June 30, 2018	704	$	20.06
Granted	1,170	$	9.91
Vested	(383)	$	20.12	$	3,732
Forfeited	(94)	$	14.33
Non-vested at December 31, 2018	1,397	$	11.93

Schedule of non-vested performance-based shares

		Weighted
		Average Grant -		Aggregate
(In thousands, except for weighted average price and life data)	Awards	date Fair Value		Intrinsic Value
Non-vested at June 30, 2018	20	$	25.58
Granted	52	$	17.69
Vested	—	$	—	$	—
Forfeited	—	$	—
Non-vested at December 31, 2018	72	$	19.92

Schedule of allocation of share-based compensation costs recognized in the Consolidated Statements of Operations by financial statement line item

	Three Months Ended				Six Months Ended
	December 31,				December 31,
(In thousands)	2018		2017		2018		2017
Selling, general and administrative expenses	$	1,095	$	1,926	$	3,309	$	3,713
Research and development expenses		199		176		400		327
Cost of sales		655		461		1,276		712
Total	$	1,949	$	2,563	$	4,985	$	4,752
Tax benefit at statutory rate	$	439	$	756	$	1,122	$	1,402